NASDAQ:MDWD - MediWound Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 56.25 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.2 (4.35%)
1 month | 3 months | 12 months
Get New MediWound Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDWD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDWD

Average Price Target: $7.50
▲ +56.25% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for MediWound in the last 3 months. The average price target is $7.50, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 56.25% upside from the last price of $4.80.


The current consensus among 4 contributing investment analysts is to buy stock in MediWound. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/10/2021OppenheimerReiterated RatingBuy$7.00High
3/2/2021AegisInitiated CoverageBuy$10.00High
2/26/2021HC WainwrightBoost Price TargetBuy$5.50 ➝ $7.00High
9/23/2020BTIG ResearchInitiated CoverageBuy$6.00Medium
8/7/2020HC WainwrightReiterated RatingBuyMedium
7/1/2020HC WainwrightReiterated RatingBuy$5.50High
6/30/2020OppenheimerReiterated RatingBuy$7.00Low
5/21/2020HC WainwrightReiterated RatingBuy$5.50Low
5/18/2020OppenheimerInitiated CoverageBuy$7.00High
1/7/2020HC WainwrightReiterated RatingBuy$5.50Low
11/15/2019HC WainwrightReiterated RatingBuy$5.50Medium
8/14/2019OppenheimerLower Price TargetOutperform$15.00 ➝ $7.00High
8/5/2019HC WainwrightInitiated CoverageBuy$5.50High
3/25/2019OppenheimerSet Price TargetBuy$15.00Low
1/22/2019OppenheimerSet Price TargetBuy$15.00Medium
11/14/2018OppenheimerSet Price TargetBuy$14.00High
9/25/2018Wells Fargo & CompanySet Price TargetBuy$11.00Medium
9/24/2018OppenheimerSet Price TargetBuy$14.00Medium
9/5/2018OppenheimerSet Price TargetBuy$14.00Low
8/8/2018Wells Fargo & CompanySet Price TargetBuy$11.00Medium
8/7/2018OppenheimerSet Price TargetBuy$14.00Medium
6/11/2018OppenheimerSet Price TargetBuy$14.00High
5/29/2018Wells Fargo & CompanyReiterated RatingBuyMedium
5/10/2018OppenheimerSet Price TargetBuy$14.00Medium
3/20/2018Wells Fargo & CompanyLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.00High
3/19/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$10.00 ➝ $12.00High
12/8/2017OppenheimerSet Price TargetBuy$10.00High
11/16/2017SunTrust BanksSet Price TargetBuy$9.00N/A
11/16/2017OppenheimerSet Price TargetBuy$10.00N/A
10/17/2017OppenheimerSet Price TargetBuy$10.00N/A
9/28/2017CowenInitiated CoverageOutperform$9.00Medium
9/28/2017Jefferies Financial GroupReiterated RatingBuy$10.00Medium
9/18/2017OppenheimerReiterated RatingBuy$10.00Low
8/25/2017Jefferies Financial GroupSet Price TargetBuy$10.00High
6/26/2017SunTrust BanksReiterated RatingBuyLow
5/25/2017AegisReiterated RatingBuy$11.00Low
5/8/2017OppenheimerSet Price TargetBuy$10.00Low
3/22/2017OppenheimerReiterated RatingBuyHigh
3/8/2017OppenheimerReiterated RatingOutperform$10.00Low
2/9/2017OppenheimerSet Price TargetBuy$10.00N/A
2/1/2017OppenheimerReiterated RatingOutperform$10.00N/A
11/28/2016AegisInitiated CoverageBuy$11.00N/A
8/17/2016Wells Fargo & CompanyInitiated CoverageOutperform$14.00N/A
7/29/2016Jefferies Financial GroupLower Price TargetBuy$15.00 ➝ $13.00N/A
(Data available from 6/20/2016 forward)
MediWound logo
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Read More

Today's Range

Now: $4.80
Low: $4.57
High: $4.80

50 Day Range

MA: $4.22
Low: $3.38
High: $5.26

52 Week Range

Now: $4.80
Low: $2.37
High: $6.07


207,780 shs

Average Volume

149,606 shs

Market Capitalization

$130.74 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of MediWound?

The following sell-side analysts have issued research reports on MediWound in the last twelve months: Aegis, BTIG Research, HC Wainwright, Oppenheimer Holdings Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for MDWD.

What is the current price target for MediWound?

4 Wall Street analysts have set twelve-month price targets for MediWound in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 56.3%. Aegis has the highest price target set, predicting MDWD will reach $10.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $6.00 for MediWound in the next year.
View the latest price targets for MDWD.

What is the current consensus analyst rating for MediWound?

MediWound currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDWD will outperform the market and that investors should add to their positions of MediWound.
View the latest ratings for MDWD.

What other companies compete with MediWound?

How do I contact MediWound's investor relations team?

MediWound's physical mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company's listed phone number is 972-8932-4010 and its investor relations email address is [email protected] The official website for MediWound is